DK3641888T3 - Plasminogenbehandling af tilstande forbundet med pai-1-overekspression - Google Patents
Plasminogenbehandling af tilstande forbundet med pai-1-overekspression Download PDFInfo
- Publication number
- DK3641888T3 DK3641888T3 DK18821458.9T DK18821458T DK3641888T3 DK 3641888 T3 DK3641888 T3 DK 3641888T3 DK 18821458 T DK18821458 T DK 18821458T DK 3641888 T3 DK3641888 T3 DK 3641888T3
- Authority
- DK
- Denmark
- Prior art keywords
- pai
- overexpression
- conditions associated
- plasminogen treatment
- plasminogen
- Prior art date
Links
- 102000013566 Plasminogen Human genes 0.000 title 1
- 108010051456 Plasminogen Proteins 0.000 title 1
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 title 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 title 1
- 230000002018 overexpression Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523901P | 2017-06-23 | 2017-06-23 | |
| PCT/IB2018/000655 WO2018234861A1 (en) | 2017-06-23 | 2018-06-22 | Plasminogen treatment of conditions associated with pai-1 overexpression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3641888T3 true DK3641888T3 (da) | 2024-01-02 |
Family
ID=64737041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18821458.9T DK3641888T3 (da) | 2017-06-23 | 2018-06-22 | Plasminogenbehandling af tilstande forbundet med pai-1-overekspression |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11826404B2 (https=) |
| EP (1) | EP3641888B1 (https=) |
| JP (1) | JP2020524689A (https=) |
| KR (1) | KR20200019217A (https=) |
| CN (1) | CN110831668B (https=) |
| AU (1) | AU2018287316B2 (https=) |
| BR (1) | BR112019027229A2 (https=) |
| CA (1) | CA3068153A1 (https=) |
| CL (1) | CL2019003789A1 (https=) |
| DK (1) | DK3641888T3 (https=) |
| ES (1) | ES2965937T3 (https=) |
| FI (1) | FI3641888T3 (https=) |
| IL (1) | IL271470B2 (https=) |
| MX (1) | MX2019015741A (https=) |
| MY (1) | MY203136A (https=) |
| NZ (1) | NZ760921A (https=) |
| RU (1) | RU2020100080A (https=) |
| SG (1) | SG11201912813SA (https=) |
| TW (1) | TWI868051B (https=) |
| WO (1) | WO2018234861A1 (https=) |
| ZA (1) | ZA202000280B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018107686A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种治疗动脉粥样硬化及其并发症的方法 |
| JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| TWI677348B (zh) | 2016-12-15 | 2019-11-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種改善心臟病變的方法 |
| EP4094775A4 (en) * | 2020-02-06 | 2023-04-19 | Talengen International Limited | METHODS AND MEDICATIONS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS |
| US20230173039A1 (en) * | 2020-03-24 | 2023-06-08 | Talengen International Limited | Method and drug for treating alzheimer disease |
| EP4122489A4 (en) * | 2020-03-24 | 2023-04-12 | Talengen International Limited | METHODS AND MEDICATIONS FOR PROMOTING THE BREAKDOWN OF MISFOLDED PROTEIN AND AGGREGATE THEREOF |
| CN115697386A (zh) * | 2020-03-24 | 2023-02-03 | 泰伦基国际有限公司 | 一种治疗帕金森病的方法和药物 |
| CN112174979B (zh) * | 2020-10-27 | 2021-09-07 | 黑龙江中医药大学 | 一种治疗多囊卵巢综合征的药物及其制备方法 |
| WO2026006092A1 (en) * | 2024-06-24 | 2026-01-02 | The Cleveland Clinic Foundation | Enzyme encapsulated nanoparticles |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5520912A (en) * | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
| US6677473B1 (en) * | 1999-11-19 | 2004-01-13 | Corvas International Inc | Plasminogen activator inhibitor antagonists |
| AU3173301A (en) * | 2000-02-11 | 2001-08-20 | European Molecular Biology Laboratory | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity |
| GB0509438D0 (en) | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
| US8318661B2 (en) * | 2006-08-28 | 2012-11-27 | Omnio Healer Ab | Candidates against infection |
| ES2453496T3 (es) | 2006-08-28 | 2014-04-08 | Omnio Healer Ab | Diana farmacológica novedosa de prevención y tratamiento de enfermedad periodontal, mejora de la cicatrización de heridas periodontales y promoción de la salud oral |
| HK1221725A1 (zh) * | 2013-08-13 | 2017-06-09 | Sanofi | 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途 |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| TW201722464A (zh) | 2015-11-10 | 2017-07-01 | 波麥堤克生化科學有限公司 | 用於傷口癒合之纖維蛋白溶酶原給藥方案 |
| JP7242057B2 (ja) | 2016-12-15 | 2023-03-20 | タレンゲン インターナショナル リミテッド | 薬物性腎損傷を予防及び治療するための方法 |
| JP7213552B2 (ja) * | 2016-12-15 | 2023-01-27 | タレンゲン インターナショナル リミテッド | 肝の繊維化を予防及び治療するための方法 |
| JP7168990B2 (ja) * | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
-
2018
- 2018-06-15 TW TW107120839A patent/TWI868051B/zh active
- 2018-06-22 DK DK18821458.9T patent/DK3641888T3/da active
- 2018-06-22 BR BR112019027229-1A patent/BR112019027229A2/pt not_active Application Discontinuation
- 2018-06-22 MX MX2019015741A patent/MX2019015741A/es unknown
- 2018-06-22 CN CN201880041573.5A patent/CN110831668B/zh active Active
- 2018-06-22 SG SG11201912813SA patent/SG11201912813SA/en unknown
- 2018-06-22 RU RU2020100080A patent/RU2020100080A/ru unknown
- 2018-06-22 MY MYPI2019007619A patent/MY203136A/en unknown
- 2018-06-22 ES ES18821458T patent/ES2965937T3/es active Active
- 2018-06-22 CA CA3068153A patent/CA3068153A1/en active Pending
- 2018-06-22 KR KR1020207001617A patent/KR20200019217A/ko not_active Ceased
- 2018-06-22 NZ NZ760921A patent/NZ760921A/en unknown
- 2018-06-22 IL IL271470A patent/IL271470B2/en unknown
- 2018-06-22 JP JP2019570806A patent/JP2020524689A/ja active Pending
- 2018-06-22 US US16/625,335 patent/US11826404B2/en active Active
- 2018-06-22 WO PCT/IB2018/000655 patent/WO2018234861A1/en not_active Ceased
- 2018-06-22 AU AU2018287316A patent/AU2018287316B2/en active Active
- 2018-06-22 EP EP18821458.9A patent/EP3641888B1/en active Active
- 2018-06-22 FI FIEP18821458.9T patent/FI3641888T3/fi active
-
2019
- 2019-12-20 CL CL2019003789A patent/CL2019003789A1/es unknown
-
2020
- 2020-01-15 ZA ZA2020/00280A patent/ZA202000280B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020524689A (ja) | 2020-08-20 |
| CL2019003789A1 (es) | 2020-07-10 |
| SG11201912813SA (en) | 2020-01-30 |
| NZ760921A (en) | 2026-01-30 |
| EP3641888B1 (en) | 2023-10-11 |
| EP3641888A4 (en) | 2021-03-10 |
| RU2020100080A3 (https=) | 2021-11-02 |
| IL271470B2 (en) | 2025-07-01 |
| KR20200019217A (ko) | 2020-02-21 |
| ZA202000280B (en) | 2021-08-25 |
| MX2019015741A (es) | 2020-11-11 |
| CN110831668A (zh) | 2020-02-21 |
| IL271470A (en) | 2020-01-30 |
| AU2018287316A1 (en) | 2020-02-06 |
| IL271470B1 (en) | 2025-03-01 |
| CN110831668B (zh) | 2024-04-12 |
| MY203136A (en) | 2024-06-10 |
| WO2018234861A1 (en) | 2018-12-27 |
| EP3641888A1 (en) | 2020-04-29 |
| US11826404B2 (en) | 2023-11-28 |
| FI3641888T3 (fi) | 2023-12-19 |
| ES2965937T3 (es) | 2024-04-17 |
| US20210330761A1 (en) | 2021-10-28 |
| TWI868051B (zh) | 2025-01-01 |
| RU2020100080A (ru) | 2021-07-23 |
| BR112019027229A2 (pt) | 2020-07-07 |
| AU2018287316B2 (en) | 2024-09-19 |
| TW201904990A (zh) | 2019-02-01 |
| CA3068153A1 (en) | 2018-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3641888T3 (da) | Plasminogenbehandling af tilstande forbundet med pai-1-overekspression | |
| DK4154882T3 (da) | Behandling af amyotrofisk lateralsklerose med pridopidin | |
| DK3471780T3 (da) | Behandling af amd med aav2-variant med aflibercept | |
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3515937T3 (da) | Behandling af refraktorisk migræne | |
| DK3973959T3 (da) | Behandling af kolestatisk kløe med seladelpar | |
| DK3785717T3 (da) | Fremgangsmåder til behandling af coronaviridae-infektioner | |
| PL3317284T3 (pl) | Związki oksazolidynonu benzoksazepiny i sposoby stosowania | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3385395T3 (da) | Fremgangsmåder til behandling af cancerpatienter med farnesyltransferase-inhibitorer | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3099298T3 (da) | Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner | |
| DK3240538T3 (da) | Anvendelse af masitinib til behandling af en underpopulation af patienter med amyotrofisk lateralsklerose | |
| DK3288577T3 (da) | Adiponectin-peptidomimetika til behandling af øjenlidelser | |
| DK3458052T3 (da) | Kombinationsbehandling af cancer | |
| DK3297653T3 (da) | Behandling af postbariatrisk hypoglykæmi med glp-1-antagonister | |
| DK3710000T3 (da) | Tradipitant til anvendelse til behandling af gastroparese | |
| LT3307267T (lt) | Išsėtinės sklerozės gydymas | |
| DK3250600T3 (da) | Behandling af autoimmune lidelser med cd154-antistoffer | |
| DK3200748T3 (da) | Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted | |
| CY2024037I1 (el) | Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων | |
| DK3302573T3 (da) | Sammensætning til behandlingen af hjernelæsioner | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
| DK3308752T3 (da) | Indretning til hyperthermisk behandling af kløe | |
| DK3727429T3 (da) | Behandling af autonomiske lidelser med botulinumtoxin |